MOPEAD (Models of Patient Engagement for Alzheimer's disease), aims to deliver a step-change in AD patient engagement strategies and a paradigm shift from late-stage diagnosis to early-stage diagnosis. It strives to improve the identification of subjects with mild cognitive impairment at an early stage.

The project assesses key tools, mechanisms and processes for community engagement, patient identification and resource utilisation. Multiple regional project sites are established to identify and test models (Runs) of efficient early identification of mild AD dementia and prodromal AD patients. The project is conducted in Germany, Sweden, Slovenia, Spain and The Netherlands. There are a total of fourteen partners in MOPEAD, find out more about our partners here. 

The Models 

Four test models (or "runs") have been developed and are currently deployed at our five MOPEAD sites.

The process is step-wise: each model is a pre-screening procedure of mild cognitive impairment that motivates the further inclusion of the patient in a more extensive series of tests. Patients undergo an immediate diagnostic process and, if eligible, are offered important support and resources: pharmacological and non-pharmacological interventions, experimental medicine (e.g. taking part in clinical trials), and recommendations to improve their quality of life.  


The first reaches out to the general public through a public engagement online form (a Citizen-Science based web page).

The second is an ‘Open House’ initiative, conducted by neurologists and neuropsychologists at memory unit offices. They test the cognitive skills of citizens who voluntarily present themselves for screening and identify those with mild cognitive disorders.


The third is a primary care-based patient engagement strategy where primary-care physicians identify patients with vascular risk factors, which are a risk factor for AD. 


The fourth is a tertiary care-based patient engagement where endocrinologists specialised in treating Type 2 Diabetes will identify patients with such risk.


The MOPEAD Objective


In clinical practice, the diagnosis of Alzheimer’s disease (AD) is still occurring late in the disease process. This creates a barrier to access available treatments and support services, as well as the opportunity to enrol in clinical trials at early stages of the disease.

Members of the scientific community, stakeholders (e.g., AD associations), regulators, and policy makers are, to varying degrees, encouraging a cultural shift towards early diagnosis of AD, at the initial symptomatic stages of the illness, as early detection of mild AD and prodromal AD is the first step toward providing patients with optimal opportunity for intervention and involvement in clinical trials.

Ultimately, MOPEAD aims to respond to the urgency of finding interventions to halt AD by stimulating a faster recruitment of patients into clinical trials.

MOPEAD will also positively influence public education about AD, memory complaints and cognitive decline.